AI has moved quickly in the life sciences making exciting breakthroughs and reframing how we think about healthcare. But beneath these breakthroughs, work is happening in places that rarely make headlines, data catalogues, validation plans, audit trails, integration layers and governance boards. That may sound less exciting than a new model that can read trial documents or spot a signal in patient data, but it is where most AI programmes will succeed or fail.
Life sciences companies want faster discovery, smarter trials, better pharmacovigilance, more efficient manufacturing and more responsive commercial operations. The problem is that AI depends on the material it is given, and in many organisations that material is still fragmented, poorly labelled, inconsistently governed or locked inside systems that were never designed to talk to one another.
A model can appear impressive in a pilot. It can summarise documents, classify cases, suggest next actions or generate insights from a narrow data set. The test comes when that same capability has to work inside a regulated environment, with live operational data, defined accountability and evidence that the output can be trusted. That is where weak foundations start to show.
In life sciences, “good enough” data is rarely good enough for AI. A missing field, an ambiguous consent status or a duplicate record can change the interpretation of an output. If data lineage is unclear, teams cannot explain where a recommendation came from. If access controls are loose, the organisation risks exposing sensitive information. If validation is treated as an afterthought, the AI system may never get beyond experiment stage.
This is why data readiness needs to be treated as a board level priority. Before asking what AI can do, organisations’ boardrooms should ask whether their data can support the answer. Is it complete enough? Is it current? Is it traceable? Does it come with the right permissions? Can teams see how it has changed over time? These questions are not administrative detail. They are the operating conditions for responsible AI.
Governance also needs to be practical, many companies already have policies for data privacy, cyber security, quality and regulatory compliance. The challenge is that AI cuts across all of them. A model used in clinical operations may involve patient privacy, software validation, medical review and vendor risk at the same time. If those teams work in sequence rather than together, delivery slows down or risk gets missed.
The better approach is to build governance into the AI lifecycle from the beginning. That means defining who owns the data, who approves the use case, who tests the model, who monitors performance and who can stop deployment if something goes wrong. It also means accepting that governance is not a one-off sign-off. AI systems can drift as data changes, processes change or user behaviour changes. Oversight has to continue after launch.
Validation is another area where life sciences must invest time and energy. Teams need documented evidence that the system works as intended, within defined limits, and that people understand those limits.
Building an effective audit trail is crucial to scaling any pilot, it requires treating the whole pipeline as a regulated record, which involves logging timestamp, actor, action, affected object ID, and old and new values. That means moving version training and pilot data into a dataset register, pinning each model release in a register by version and logging every inference with its prompt, parameters, model version and human sign off. This meets ALCOA+ principles, a globally recognised framework that ensures data integrity and quality, so any pilot can be scaled without sounding regulatory alarm bells.
Infrastructure matters because it determines whether this can be done repeatedly. Many AI pilots are built as exceptions. They use copied data, manual extracts and one-off pipelines. That may be useful for learning, but it is not a foundation for scaled adoption. Life sciences organisations need environments where data can be accessed securely, models can be tested safely, outputs can be logged, and changes can be reviewed without rebuilding everything each time.
Cost visibility should be front and centre of mind when working alongside any AI project. Organisations running compute intensive workloads in life sciences, such as genomics research and diagnostics, often face significant cost management challenges when moving to the cloud. High performance computing environments where thousands of compute nodes work in parallel can generate unpredictable spend if there is no structured approach to monitoring utilisation. Without clear visibility into where resources are over provisioned or under used, finance teams risk losing control of budgets that were already under pressure. A disciplined FinOps approach, with business intelligence dashboards tracking spend across projects and pilots, can turn that visibility into meaningful savings.
The choice of platform will vary, some organisations will use cloud services from AWS, Microsoft Azure or Google Cloud. Others will build around data platforms such as Snowflake or Databricks, alongside specialist clinical, regulatory and laboratory systems. The brand is less important than the architecture. The question is whether the infrastructure supports control, traceability and reuse, rather than creating another isolated layer of complexity.
There is also a cultural point here, AI exposes old data problems that people have learned to work around. Scientists, clinicians, regulatory teams and operational staff often know where the gaps are, but those gaps have been absorbed into local practice. AI removes that tolerance. It needs definitions to be explicit. It needs exceptions to be visible. It needs decisions to be recorded.
That can feel uncomfortable, especially in organisations where data ownership has been unclear for years. But it is also an opportunity, the work needed for AI readiness often improves the business well beyond AI. Cleaner data, clearer governance and better integration help reporting, compliance, collaboration and operational resilience. Even if a particular AI use case changes, the foundation remains useful.
The next phase of AI in life sciences will be less about who has the most dramatic demo and more about who can make AI dependable in daily work. That depends on patient, disciplined engineering, cost control and governance. It depends on data that can be trusted under scrutiny and is designed to meet regulatory needs from the very start.
AI will transform life sciences, but only if organisations do the unglamorous work first. Those who fail to take into account their data foundations risk falling behind or worse, not complying with regulations. But those who get the foundations right are set up to thrive and create the breakthroughs to usher in the next era of healthcare.
Author Bio
